Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kwon, Jennie H.
Olsen, Margaret A.
and
Dubberke, Erik R.
2015.
The Morbidity, Mortality, and Costs Associated with Clostridium difficile Infection.
Infectious Disease Clinics of North America,
Vol. 29,
Issue. 1,
p.
123.
Heimann, S. M.
Vehreschild, J. J.
Cornely, O. A.
Wisplinghoff, H.
Hallek, M.
Goldbrunner, R.
Böttiger, B. W.
Goeser, T.
Hölscher, A.
Baldus, S.
Müller, F.
Jazmati, N.
Wingen, S.
Franke, B.
and
Vehreschild, M. J. G. T.
2015.
Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.
Infection,
Vol. 43,
Issue. 6,
p.
707.
Le Monnier, A.
Duburcq, A.
Zahar, J.-R.
Corvec, S.
Guillard, T.
Cattoir, V.
Woerther, P.-L.
Fihman, V.
Lalande, V.
Jacquier, H.
Mizrahi, A.
Farfour, E.
Morand, P.
Marcadé, G.
Coulomb, S.
Torreton, E.
Fagnani, F.
and
Barbut, F.
2015.
Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals.
Journal of Hospital Infection,
Vol. 91,
Issue. 2,
p.
117.
Zhang, Shanshan
Palazuelos-Munoz, Sarah
Balsells, Evelyn M.
Nair, Harish
Chit, Ayman
and
Kyaw, Moe H.
2016.
Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study.
BMC Infectious Diseases,
Vol. 16,
Issue. 1,
Chopra, Teena
Goldstein, Ellie J.C.
and
Gorbach, Sherwood L.
2016.
Rethinking Strategies to Select Antibiotic Therapy inClostridium difficileinfection.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 36,
Issue. 12,
p.
1281.
McFarland, Lynne Vernice
Ozen, Metehan
Dinleyici, Ener Cagri
and
Goh, Shan
2016.
Comparison of pediatric and adult antibiotic-associated diarrhea andClostridium difficileinfections.
World Journal of Gastroenterology,
Vol. 22,
Issue. 11,
p.
3078.
Couture-Cossette, Antoine
Carignan, Alex
Ilangumaran, Subburaj
and
Valiquette, Louis
2017.
Bezlotoxumab for the prevention ofClostridium difficilerecurrence.
Expert Opinion on Biological Therapy,
p.
1.
Wilcox, Mark H.
Ahir, Harblas
Coia, John E.
Dodgson, Andrew
Hopkins, Susan
Llewelyn, Martin J.
Settle, Chris
Mclain-Smith, Susan
and
Marcella, Stephen W.
2017.
Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life.
Journal of Antimicrobial Chemotherapy,
Vol. 72,
Issue. 9,
p.
2647.
Zilberberg, Marya D.
Shorr, Andrew F.
Jesdale, William M.
Tjia, Jennifer
and
Lapane, Kate
2017.
Recurrent Clostridium difficile infection among Medicare patients in nursing homes.
Medicine,
Vol. 96,
Issue. 10,
p.
e6231.
Pak, Theodore R.
Chacko, Kieran I.
O’Donnell, Timothy
Huprikar, Shirish S.
van Bakel, Harm
Kasarskis, Andrew
and
Scott, Erick R.
2017.
Estimating Local Costs Associated WithClostridium difficileInfection Using Machine Learning and Electronic Medical Records.
Infection Control & Hospital Epidemiology,
Vol. 38,
Issue. 12,
p.
1478.
Dieterle, Michael G.
and
Young, Vincent B.
2017.
Reducing Recurrence of C. difficile Infection.
Cell,
Vol. 169,
Issue. 3,
p.
375.
Reveles, Kelly R.
Backo, Jennifer L.
Corvino, Frank A.
Zivkovic, Marko
and
Broderick, Kelly C.
2017.
Fidaxomicin versus Vancomycin as a First‐Line Treatment for Clostridium difficile–Associated Diarrhea in Specific Patient Populations: A Pharmacoeconomic Evaluation.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
Vol. 37,
Issue. 12,
p.
1489.
McFarland, Lynne V.
2017.
Primary prevention of Clostridium difficile infections – how difficult can it be?.
Expert Review of Gastroenterology & Hepatology,
Vol. 11,
Issue. 6,
p.
507.
Barlam, Tamar F.
Soria-Saucedo, Rene
Ameli, Omid
Cabral, Howard J.
Kaplan, Warren A.
Kazis, Lewis E.
and
Deshpande, Abhishek
2018.
Retrospective analysis of long-term gastrointestinal symptoms after Clostridium difficile infection in a nonelderly cohort.
PLOS ONE,
Vol. 13,
Issue. 12,
p.
e0209152.
Basu, Anirban
Prabhu, Vimalanand S
Dorr, Mary Beth
Golan, Yoav
Dubberke, Erik R
Cornely, Oliver A
Heimann, Sebastian M
Pedley, Alison
Xu, Ruifeng
Hanson, Mary E
and
Marcella, Stephen
2018.
Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials.
Open Forum Infectious Diseases,
Vol. 5,
Issue. 11,
Ford, Diana C.
Schroeder, Mary C.
Ince, Dilek
and
Ernst, Erika J.
2018.
Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients.
American Journal of Health-System Pharmacy,
Vol. 75,
Issue. 15,
p.
1110.
Dubberke, Erik R
Lee, Christine H
Orenstein, Robert
Khanna, Sahil
Hecht, Gail
and
Gerding, Dale N
2018.
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection.
Clinical Infectious Diseases,
Vol. 67,
Issue. 8,
p.
1198.
Zilberberg, Marya D.
Nathanson, Brian H.
Marcella, Stephen
Hawkshead, John Jay
and
Shorr, Andrew F.
2018.
Hospital readmission with Clostridium difficile infection as a secondary diagnosis is associated with worsened outcomes and greater revenue loss relative to principal diagnosis.
Medicine,
Vol. 97,
Issue. 36,
p.
e12212.
Cornely, Oliver A
Watt, Maureen
McCrea, Charles
Goldenberg, Simon D
and
De Nigris, Enrico
2018.
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
Journal of Antimicrobial Chemotherapy,
Vol. 73,
Issue. 9,
p.
2529.
Zhang, Dongmu
Prabhu, Vimalanand S
and
Marcella, Stephen W
2018.
Attributable Healthcare Resource Utilization and Costs for Patients With Primary and Recurrent Clostridium difficile Infection in the United States.
Clinical Infectious Diseases,
Vol. 66,
Issue. 9,
p.
1326.